Mononine Soon Will No Longer Be Available to Treat Hemophilia B

Mononine Soon Will No Longer Be Available to Treat Hemophilia B
4
(1)

Mononine, a long-standing treatment to prevent and control bleeding in hemophilia B, will be discontinued due to declining demand in recent years.

CSL Behring, the therapy’s manufacturer, said the decision was based on the emergence of next-generation hemophilia B treatments now in greater use.

“Over time, patients have transitioned from older therapies to newer, next generation treatment options, and very few patients currently remain on MONONINE in the US,” CSL Behring wrote in a statement published on the Hemophilia Federation of America’s website. “Accordingly, we are discontinuing MONONINE.”

The medication is expected be available through mid-2021, based on current supply, giving patients time to move to another therapy. 

“We understand this news may be challenging for the patients who remain on MONONINE,” the company added, encouraging those using Mononine “to talk with their Healthcare Professional soon to discuss alternate treatment options.” 

Questions from patients and healthcare professionals can be directed to the company’s medical information center at 1-800-504-5434, Monday–Friday 9 a.m. to 5 p.m. ET.

Mononine is a plasma-derived clotting factor concentrate, one of the major classes of approved hemophilia B treatments. Replacement therapy involves using human plasma (the cell-free liquid part of blood) to replenish factor IX, the blood coagulation protein missing or defective in people with hemophilia B.

Mononine became the first highly purified factor IX approved by the U.S. Food and Drug Administration (FDA) in 1992. It is administered by intravenous infusion (directly into the bloodstream).

More recent options for hemophilia B treatment include AlphaNine SD, also a plasma-derived factor therapy to improve clotting and prevent or lessen excessive or uncontrolled bleeding. This intravenous injection treatment, marketed by Grifols, was approved by the FDA in 1996.

Rixubis, a replacement therapy approved by the FDA in 2013 and marketed by Takeda, is a recombinant factor IX product, which means that it is engineered to be similar to the body’s own clotting protein. In turn, AlprolixSanofi Genzyme‘s recombinant therapy for hemophilia B — is an extended half-life medication, as it has been designed to remain in the body longer and requires less frequent administration.

In people with severe hemophilia B, spontaneous bleeds may occur in the absence of injury, surgery, or other obvious cause. They may require regular, prophylactic therapy of factor IX to prevent bleeding.

Aisha Abdullah received a B.S. in biology from the University of Houston and a Ph.D. in neuroscience from Weill Cornell Medical College, where she studied the role of microRNA in embryonic and early postnatal brain development. Since finishing graduate school, she has worked as a science communicator making science accessible to broad audiences.
Total Posts: 46

José holds a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

×
Aisha Abdullah received a B.S. in biology from the University of Houston and a Ph.D. in neuroscience from Weill Cornell Medical College, where she studied the role of microRNA in embryonic and early postnatal brain development. Since finishing graduate school, she has worked as a science communicator making science accessible to broad audiences.
Latest Posts
  • acquired hemophilia A study
  • Mononine coming off market

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This